Rani Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Rani Therapeutics Holdings
RANI Stock  USD 1.24  0.01  0.80%   
Rani Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Rani Therapeutics' valuation are provided below:
Gross Profit
1.2 M
Market Capitalization
152.1 M
Enterprise Value Revenue
111.9777
Revenue
1.2 M
Earnings Share
(0.77)
We have found one hundred twenty available trending fundamental ratios for Rani Therapeutics, which can be analyzed and compared to other ratios and to its competitors. Traders should compare all of Rani Therapeutics recent fundamentals against the fundamentals between 2010 and 2026 to make sure the company is sustainable this year.

Rani Therapeutics Total Revenue

691,466

Check Rani Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Rani Therapeutics' main balance sheet or income statement drivers, such as Interest Income of 1.3 M, Depreciation And Amortization of 742.1 K or Interest Expense of 6.1 M, as well as many indicators such as Price To Sales Ratio of 41.46, Dividend Yield of 0.0 or PTB Ratio of 18.51. Rani financial statements analysis is a perfect complement when working with Rani Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Rani Stock
Check out the analysis of Rani Therapeutics Correlation against competitors.

Rani Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets57.2 M33 M42.7 M
Slightly volatile
Short and Long Term Debt Total33.5 M26.7 M78.8 M
Slightly volatile
Other Current Liabilities1.4 M1.9 M2.4 M
Slightly volatile
Total Current Liabilities24 M22.9 M7.2 M
Slightly volatile
Property Plant And Equipment Net6.3 M7.6 M5.2 M
Slightly volatile
Accounts Payable968.4 K1.6 M564.4 K
Slightly volatile
Cash3.2 M3.4 M23.5 M
Very volatile
Non Current Assets Total6.6 M7.9 M6.2 M
Slightly volatile
Non Currrent Assets Other210.3 K221.4 K1.2 M
Slightly volatile
Cash And Short Term Investments23.6 M24.9 M34.1 M
Slightly volatile
Net Receivables519.6 K385.2 K361.9 K
Pretty Stable
Common Stock Shares Outstanding24.7 M32.7 M21.2 M
Slightly volatile
Liabilities And Stockholders Equity57.2 M33 M42.7 M
Slightly volatile
Non Current Liabilities Total11.3 M11.9 M84.7 M
Slightly volatile
Inventory0.80.90.9824
Slightly volatile
Other Current Assets1.6 M1.9 M802.3 K
Slightly volatile
Other Stockholder Equity126.7 M120.6 M33.9 M
Slightly volatile
Total Liabilities55.3 M29.8 M92.7 M
Slightly volatile
Property Plant And Equipment Gross8.8 M13 M7.1 M
Slightly volatile
Total Current Assets52.4 M26.8 M36.7 M
Slightly volatile
Capital Stock4.3 K4.5 K431.3 K
Slightly volatile
Net Working Capital8.4 M8.9 M28.7 M
Slightly volatile
Common Stock4.3 K4.5 K431.3 K
Slightly volatile
Property Plant Equipment5.4 M6.9 M4.9 M
Slightly volatile
Long Term Debt18.1 M11.1 M8.7 M
Slightly volatile
Short and Long Term Debt18.1 M17.2 M4.7 M
Slightly volatile
Short Term Debt19.9 M18.9 M4.6 M
Slightly volatile
Noncontrolling Interest In Consolidated Entity29.7 M33.4 M36.5 M
Slightly volatile
Common Stock Total Equity4 K4.5 K4.9 K
Slightly volatile
Long Term Debt Total23.3 M26.2 M28.6 M
Slightly volatile
Capital Surpluse60.7 M68.3 M74.5 M
Slightly volatile
Non Current Liabilities Other47.2 K53.1 K58 K
Slightly volatile

Rani Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Interest Income1.3 M2 M832.5 K
Slightly volatile
Depreciation And Amortization742.1 K1.2 M649.9 K
Slightly volatile
Interest Expense6.1 M5.8 M1.4 M
Slightly volatile
Selling General Administrative20.8 M27.5 M11.4 M
Slightly volatile
Other Operating Expenses51.9 M62.5 M38.2 M
Slightly volatile
Research Development30.4 M30.7 M26.4 M
Slightly volatile
Total Operating Expenses51.8 M62.5 M38.2 M
Slightly volatile
Reconciled Depreciation732.4 K1.2 M646.2 K
Slightly volatile
Cost Of Revenue853.6 K739.8 K1.2 M
Slightly volatile
Non Operating Income Net Other998.4 K1.1 M1.2 M
Slightly volatile
Selling And Marketing Expenses657.6 K739.8 K807.5 K
Slightly volatile

Rani Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow5.4 M5.7 M40.4 M
Pretty Stable
Depreciation742.1 K1.2 M649.9 K
Slightly volatile
Capital Expenditures229.1 K241.2 K1.2 M
Slightly volatile
Total Cash From Financing Activities11.6 M12.2 M13.2 M
Slightly volatile
End Period Cash Flow3.6 M3.8 M23.6 M
Very volatile
Other Cashflows From Investing Activities769.3 K1.4 M426.5 K
Slightly volatile
Dividends Paid23.7 M26.7 M29.1 M
Slightly volatile
Cash Flows Other Operating404 K454.5 K496.1 K
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio41.4643.64169
Slightly volatile
Days Sales Outstanding130137186
Pretty Stable
Stock Based Compensation To Revenue9.5714.0310.0104
Slightly volatile
Capex To Depreciation0.280.32.1399
Slightly volatile
EV To Sales69.0372.67225
Slightly volatile
Payables Turnover1.021.141.2463
Slightly volatile
Sales General And Administrative To Revenue22.0120.969.9547
Slightly volatile
Research And Ddevelopement To Revenue23.8929.8524.6167
Very volatile
Capex To Revenue0.280.31.1938
Slightly volatile
Cash Per Share1.061.121.6426
Slightly volatile
Days Payables Outstanding230259283
Slightly volatile
Income Quality0.690.721.1133
Very volatile
Current Ratio1.631.728.237
Pretty Stable
Receivables Turnover2.422.763.1892
Slightly volatile
Capex Per Share0.01030.01080.0635
Slightly volatile
Revenue Per Share0.05040.03250.0516
Very volatile
Interest Debt Per Share1.891.44.0635
Slightly volatile
Debt To Assets1.470.933.2064
Slightly volatile
Operating Cycle130137186
Pretty Stable
Days Of Payables Outstanding230259283
Slightly volatile
Ebt Per Ebit1.020.650.948
Slightly volatile
Quick Ratio1.631.728.237
Pretty Stable
Net Income Per E B T0.690.580.8187
Slightly volatile
Cash Ratio0.210.226.617
Very volatile
Days Of Sales Outstanding130137186
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio1.141.161.0626
Pretty Stable
Fixed Asset Turnover0.220.140.2185
Very volatile
Debt Ratio1.470.933.2064
Slightly volatile
Price Sales Ratio41.4643.64169
Slightly volatile
Asset Turnover0.02710.03230.0351
Slightly volatile

Rani Fundamental Market Drivers

Rani Upcoming Events

27th of March 2024
Upcoming Quarterly Report
View
8th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
27th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Rani Therapeutics Financial Statements

Investors use fundamental indicators, such as Rani Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Although Rani Therapeutics' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Current Deferred Revenue-1.3 M-1.2 M
Total Revenue925.2 K691.5 K
Cost Of Revenue739.8 K853.6 K
Stock Based Compensation To Revenue 14.03  9.57 
Sales General And Administrative To Revenue 20.96  22.01 
Research And Ddevelopement To Revenue 29.85  23.89 
Capex To Revenue 0.30  0.28 
Revenue Per Share 0.03  0.05 
Ebit Per Revenue(59.64)(62.62)

Currently Active Assets on Macroaxis

FSLYFastly Class A
MOBMobilicom Limited American
CMGChipotle Mexican Grill
CSANCosan SA ADR
RKTRocket Companies
When determining whether Rani Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Rani Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Rani Therapeutics Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Rani Therapeutics Holdings Stock:
How To Invest In Rani
Details
Is Rani Stock a good investment?
Details
What is Rani Therapeutics' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Rani Therapeutics Correlation against competitors.
You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Is there potential for Biotechnology market expansion? Will Rani introduce new products? Factors like these will boost the valuation of Rani Therapeutics. Anticipated expansion of Rani directly elevates investor willingness to pay premium valuations. Understanding fair value requires weighing current performance against future potential. All the valuation information about Rani Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.77)
Revenue Per Share
0.032
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.96)
Return On Equity
(11.88)
Understanding Rani Therapeutics requires distinguishing between market price and book value, where the latter reflects Rani's accounting equity. The concept of intrinsic value - what Rani Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Market sentiment, economic cycles, and investor behavior can push Rani Therapeutics' price substantially above or below its fundamental value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
It's important to distinguish between Rani Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Rani Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Rani Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY